Enoxaparin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:57:51Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:57, 20 March 2026
Line 59:		Line 59:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:52Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:25, 20 March 2026
Line 61:		Line 61:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:02Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 48: / Line 48: @@
 *Excretion: urine
 *Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III
 ==See Also==

Rossdonaldson1: /* Therapeutic anticoagulation */

2019-11-28T17:58:52Z

Therapeutic anticoagulation

← Older revision		Revision as of 17:58, 28 November 2019
Line 5:		Line 5:

	==Adult Dosing==		==Adult Dosing==
	===~~Therapeutic anticoagulation===~~		===<u>Therapeutic</u> anticoagulation (e.g. treating [[DVT]]/[[PE]], [[unstable angina]])===
	''<u>~~Treating~~</u> [[DVT]]/[[PE]], [[unstable angina]]''
	*1mg/kg SC q12h		*1mg/kg SC q12h

Rossdonaldson1: /* DVT prophylaxis */

2019-11-28T17:57:55Z

DVT prophylaxis

← Older revision		Revision as of 17:57, 28 November 2019
Line 10:		Line 10:

	{{Chemical prophylaxis of VTE}}		{{Chemical prophylaxis of VTE}}

	~~===[[DVT]] ''prophylaxis''===~~
	*40mg SC daily
	~~30mg SubQ q12 hrs (if Cr Clearance > 30)~~

	==Pediatric Dosing==		==Pediatric Dosing==

Rossdonaldson1: /* Therapeutic anticoagulation */

2019-11-28T17:56:47Z

Therapeutic anticoagulation

← Older revision		Revision as of 17:56, 28 November 2019
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	===Therapeutic anticoagulation===		===Therapeutic anticoagulation===
	''Treating [[DVT]]/[[PE]], [[unstable angina]]''		''<u>Treating</u> [[DVT]]/[[PE]], [[unstable angina]]''
	*1mg/kg SC q12h		*1mg/kg SC q12h

Rossdonaldson1: /* Adult Dosing */

2019-11-28T17:56:23Z

Adult Dosing

← Older revision		Revision as of 17:56, 28 November 2019
Line 5:		Line 5:

	==Adult Dosing==		==Adult Dosing==
	*[[DVT]] ''prophylaxis'': 40mg SC daily		===Therapeutic anticoagulation===
	*Therapeutic anticoagulation (~~e.g. treating DVT/PE, unstable angina~~)~~: 1mg/kg SC q12h~~		''Treating [[DVT]]/[[PE]], [[unstable angina]]''
			*1mg/kg SC q12h

			{{Chemical prophylaxis of VTE}}

			===[[DVT]] ''prophylaxis''===
			*40mg SC daily
			30mg SubQ q12 hrs (if Cr Clearance > 30)

	==Pediatric Dosing==		==Pediatric Dosing==

ClaireLewis at 19:19, 22 September 2019

2019-09-22T19:19:16Z

← Older revision		Revision as of 19:19, 22 September 2019
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Low molecular weight heparin]]		*Type: [[Low molecular weight heparin]]
	*Dosage Forms:		*Dosage Forms: subcutaneous
	*Common Trade Names: Lovenox		*Common Trade Names: Lovenox

	==Adult Dosing==		==Adult Dosing==
			*[[DVT]] ''prophylaxis'': 40mg SC daily
			*Therapeutic anticoagulation (e.g. treating DVT/PE, unstable angina): 1mg/kg SC q12h

	==Pediatric Dosing==		==Pediatric Dosing==
			''Off-label''
			*DVT prophylaxis:
			**<2 months: 0.75 mg/kg SC q12hr
			**≥2 months: 0.5 mg/kg SC q12h
			*Therapeutic anticoagulation:
			**<2 months: 1.5 mg/kg SC q12hr
			**≥2 months: 1 mg/kg SC q12hr

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: B
	*Lactation:		*Lactation: Unknown risk
	*Renal Dosing		*Renal Dosing
	**Renal impairment (creatinine clearance <30)		**Renal impairment (creatinine clearance <30)
	***Use 50% of usual dose or use UFH instead		***Use 50% of usual dose or use UFH instead
	**Adult		*Hepatic Dosing: not established
	**Pediatric
	*Hepatic Dosing
	**Adult
	**Pediatric
	*Obesity		*Obesity
	**Weight-based dosing safe up to 190kg (no data available thereafter)		**Weight-based dosing safe up to 190kg (no data available thereafter)
Line 37:		Line 42:

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: 4.5h
	*Metabolism:		*Metabolism: hepatic
	*Excretion:		*Excretion: urine
	*Mechanism of Action:		*Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III

	==See Also==		==See Also==

Neil.m.young: Text replacement - "Cr " to "creatinine "

2016-08-11T06:11:58Z

Text replacement - "Cr " to "creatinine "

← Older revision		Revision as of 06:11, 11 August 2016
Line 12:		Line 12:
	*Lactation:		*Lactation:
	*Renal Dosing		*Renal Dosing
	**Renal impairment (Cr clearance <30)		**Renal impairment (creatinine clearance <30)
	***Use 50% of usual dose or use UFH instead		***Use 50% of usual dose or use UFH instead
	**Adult		**Adult

Neil.m.young: Text replacement - "==Sources==" to "==References=="

2016-06-26T12:23:14Z

Text replacement - "==Sources==" to "==References=="

← Older revision		Revision as of 12:23, 26 June 2016
Line 47:		Line 47:
	*[[Anticoagulant reversal for life-threatening bleeds]]		*[[Anticoagulant reversal for life-threatening bleeds]]

	==~~Sources~~==		==References==
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]